Overexpression of MDR-related p170 glycoprotein in chronic myeloid leukemia.

Abstract

BACKGROUND AND METHODS:

Philadelphia (Ph) positive chronic myeloid leukemia (CML) cannot be induced into a true remission with conventional chemotherapy. Blast cells and precursors obtained from 51 Ph+ CML cases were assayed for expression of the multidrug resistance (MDR)-associated glycoprotein (p170) by immunocytochemistry (APAAP) with the MRK-16 monoclonal antibody.

RESULTS AND CONCLUSIONS:

Positive cells were found in 11/17 cases in chronic phase (65%), in 4/8 cases in accelerated phase, and in 23/26 cases in blastic phase (89%). The proportion of positive cells, which ranged between less than 1% and 95%, was higher in blastic phase (mean 32 +/- 29.9) than in chronic phase (mean 3 +/- 5.3) (p = 0.006). These findings show that p170 overexpression is common in Ph+ CML, especially after progression to blastic phase, and suggest that p170-related MDR may contribute significantly to treatment failure.

• Authors: A Michelutti, M Michieli, D Damiani, C Melli, A Geromin, D Russo, R Fanin, M Baccarani
• Journal: Haematologica (Haematologica) 1994 May-Jun Vol. 79 Issue 3 Pg. 200-4 ISSN: 0390-6078 [Print] Italy
• PMID: 7926967 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't)

Chemical References

• ATP Binding Cassette Transporter, Subfamily B, Member 1

Topics

• ATP Binding Cassette Transporter, Subfamily B, Member 1 (biosynthesis)
• Drug Resistance, Multiple (physiology)
• Humans
• Leukemia, Myelogenous, Chronic, BCR-ABL Positive (blood)
• Molecular Weight
• Retrospective Studies